Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 28:12:827755.
doi: 10.3389/fonc.2022.827755. eCollection 2022.

High Systemic Immune Inflammation Index Is Associated With Low Skeletal Muscle Quantity in Resectable Pancreatic Ductal Adenocarcinoma

Mohammad Hosein Aziz  1 , Jelle C van Dongen  1 , Lawlaw Saida  2 , Mustafa Suker  1 , Jeroen L A van Vugt  1 , Yordi van Putten  1 , Kostandinos Sideras  3 , Jesse V Groen  4 , J Sven D Mieog  4 , Claudia J Lucassen  5 , Anneke Droop  5 , Katya Mauff  6 , Shirin Shahbazi Feshtali  7 , Bas Groot Koerkamp  1 , Dana A M Mustafa  2 , Casper J van Eijck  1   2
Affiliations

High Systemic Immune Inflammation Index Is Associated With Low Skeletal Muscle Quantity in Resectable Pancreatic Ductal Adenocarcinoma

Mohammad Hosein Aziz et al. Front Oncol. .

Abstract

Background and aims: Failing immune surveillance in pancreatic ductal adenocarcinoma (PDAC) is related to poor prognosis. PDAC is also characterized by its substantial alterations to patients' body composition. Therefore, we investigated associations between the host systemic immune inflammation response and body composition in patients with resected PDAC.

Methods: Patients who underwent a pancreatectomy for PDAC between 2004 and 2016 in two tertiary referral centers were included. Skeletal muscle mass quantity and muscle attenuation, as well as subcutaneous and visceral adipose tissue at the time of diagnosis, were determined by CT imaging measured transversely at the third lumbar vertebra level. Baseline clinicopathological characteristics, laboratory values including the systemic immune inflammation index (SIII), postoperative, and survival outcomes were collected.

Results: A total of 415 patients were included, and low skeletal muscle mass quantity was found in 273 (65.7%) patients. Of the body composition indices, only low skeletal muscle mass quantity was independently associated with a high (≥900) SIII (OR 7.37, 95% CI 2.31-23.5, p=0.001). The SIII was independently associated with disease-free survival (HR 1.86, 95% CI 1.12-3.04), and cancer-specific survival (HR 2.21, 95% CI 1.33-3.67). None of the body composition indices were associated with survival outcomes.

Conclusion: This study showed a strong association between preoperative low skeletal muscle mass quantity and elevated host systemic immune inflammation in patients with resected PDAC. Understanding how systemic inflammation may contribute to changes in body composition or whether reversing these changes may affect the host systemic immune inflammation response could expose new therapeutic possibilities for improving patients' survival outcomes.

Keywords: body composition; pancreatic ductal adenocarcinoma; skeletal muscle mass; survival; systemic immune inflammation index.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Abdominal CT images at the third lumbar vertebrae used to quantify body composition variables. (A) Skeletal muscles (blue) (B) Subcutaneous adipose tissue (yellow) (C) Visceral adipose tissue (yellow).
Figure 2
Figure 2
(A) Disease-free survival of the total cohort. (B) Cancer-specific survival of the total cohort. (C) Disease-free survival of the total cohort. (D) Cancer-specific survival of the total cohort.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. . Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. Int J Cancer (2015) 136:E359–386. doi: 10.1002/ijc.29210 - DOI - PubMed
    1. Kleeff J, Korc M, Apte M, Vecchia C, Johnson CD, Biankin AV, et al. . Pancreatic Cancer. Nat Rev Dis Primers (2016) 2:16022. doi: 10.1038/nrdp.2016.22 - DOI - PubMed
    1. Bengtsson A, Andersson R, Ansari D. The Actual 5-Year Survivors of Pancreatic Ductal Adenocarcinoma Based on Real-World Data. Sci Rep (2020) 10:16425. doi: 10.1038/s41598-020-73525-y - DOI - PMC - PubMed
    1. Dell'Aquila E, Fulgenzi CAM, Minelli A, Citarella F, Stellato M, Pantano F, et al. . Prognostic and Predictive Factors in Pancreatic Cancer. Oncotarget (2020) 11:924–41. doi: 10.18632/oncotarget.27518 - DOI - PMC - PubMed
    1. Aziz MH, Sideras K, Aziz NA, Mauff K, Haen R, Roos D, et al. . The Systemic-Immune-Inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and Its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study. Ann Surg (2019) 270:139–46. doi: 10.1097/SLA.0000000000002660 - DOI - PubMed

LinkOut - more resources